CRESCENT CAPITAL BDC CCAP 深 沪
等待开盘 07-22 09:30:00 美东时间
14.41
-0.080
-0.55%
华盛通- 最 高14.59
- 今 开14.53
- 成交量 29.54万股
- 最 低 14.34
- 昨 收 14.49
- 总市值 5.34亿
- 52周最高 19.25
- 市盈率 静 7.25
- 换手率 0.80%
- 52周最低 13.07
- 委 比 -47.82%
- 总股本 3706.15万
- 历史最高 19.25
- 量 比 1.18
- 振 幅 1.73%
- 历史最低 -3.70
- 每 手 1
- 风险率 1.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅2840.31%！Mersana Therapeutics获Truist Securities升目标价至10美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130419824951111681.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Truist Securities：维持Mersana Therapeutics(MRSN)"买入"评级，目标价从9美元升至10美元</p> <p>• Guggenheim：维持Cabaletta Bio(CABA)"买入
05-17 08:44
Crescent Capital BDC Navigates Earnings Amid Challenges
Crescent Capital Bdc, Inc. (($CCAP)) has held its Q1 earnings call. Read on for...
05-16 08:25
Crescent Capital BDC Q1 Net investment income per share $0.45 Misses $0.52 Estimate, Total investment income $42.13M Miss $45.08M Estimate
Crescent Capital BDC (NASDAQ:CCAP) reported quarterly earnings of $0.45 per share which missed the analyst consensus estimate of $0.52 by 13.46 percent. This is a 28.57 percent decrease over earnings of $0.63 per share
05-15 04:12
Earnings Scheduled For May 14, 2025
Companies Reporting Before The Bell • Cellebrite DI (NASDAQ:CLBT) is expected t...
05-14 16:32
Crescent Capital BDC declares $0.42 quarterly dividend
Crescent Capital BDC (NASDAQ:CCAP) declares $0.42/share quarterly dividend. Payable June 13; for shareholders of record May 30; ex-div May 30. The company decide special cash dividends related to undi...
05-13 23:34
Commscope targets $1-1.05B adjusted EBITDA in 2025 amid strong segment growth
Earnings Call Insights: CommScope (COMM) Q1 2025 Management View CEO Charles Treadway reported core net sales of $1.112 billion for Q1 2025, marking a 23% year-over-year increase, with core adjusted E...
05-02 02:39
美股大行评级 | 超多美股遭下调评级！高盛：下调美国航空集团评级至"卖出"，目标价从16美元下调至8美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1117013356914663424.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持FTC Solar(FTCI)"买入"评级，目标价从1.5美元升至5美元</p> <p>• 摩根士丹利：维持艾伯维(ABBV)"超配"评级，目标价从239美元升至241美
04-10 09:00
美股大行评级 | 潜在涨幅147.43%！HC Wainwright & Co.上调Pacira BioSciences目标价至65美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1116650478822592513.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Pacira BioSciences(PCRX)"买入"评级，目标价从48美元升至65美元</p> <p>• 瑞穗：上调Amylyx Pharmaceuticals(AM
04-09 08:50
美股大行评级 | 潜在涨幅75%！Solar Edge获高盛升目标价至31美元，维持买入评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1099980218194210816.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Maxim Group：维持Chemomab Therapeutics(CMMB)"买入"评级，目标价从4美元升至7美元</p> <p>• Citizens Capital Markets：维持德纳维制药(DVAX)"跑赢
02-24 11:50
Crescent Capital BDC Earnings Call: Stability Amid Challenges
Crescent Capital Bdc, Inc. (($CCAP)) has held its Q4 earnings call. Read on for...
02-21 08:24
